These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31755967)

  • 1. Correlation of Macular Thickness and Visual Acuity in DME Treated by Two Doses of Intravitreal Ziv-Aflibercept Versus Bevacizumab: Analysis of a Randomized, Three-Armed Clinical Trial.
    Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):684-690. PubMed ID: 31755967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
    Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
    Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
    Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.
    Nourinia R; Ahmadieh H; Nekoei E; Malekifar P; Tofighi Z
    Retina; 2018 May; 38(5):970-975. PubMed ID: 28426622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema.
    Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
    Ophthalmol Retina; 2018 May; 2(5):428-440. PubMed ID: 31047323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.
    Ghanbari H; Kianersi F; Sonbolestan SA; Abtahi MA; Akbari M; Abtahi ZA; Abtahi SH
    Int Ophthalmol; 2017 Aug; 37(4):867-874. PubMed ID: 27624173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections.
    Singh SR; Chattannavar G; Ayachit A; Pimentel MC; Alfaro A; Tiwari S; Heranjal A; Subramanyam A; Braimah IZ; Dhami A; Sachdev P; Mansour A; Chhablani J
    Semin Ophthalmol; 2020 Jan; 35(1):2-6. PubMed ID: 31690175
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial.
    Entezari M; Flavarjani ZK; Ramezani A; Nikkhah H; Karimi S; Moghadam HF; Daftarian N; Yaseri M
    Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2375-2380. PubMed ID: 31401683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
    Singh SR; Sahoo NK; Goud NR; Chhablani J
    Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Doses of Intravitreal Ziv-Aflibercept versus Bevacizumab in Treatment of Diabetic Macular Edema: A Three-Armed, Double-Blind Randomized Trial.
    Baghi A; Jabbarpoor Bonyadi MH; Ramezani A; Azarmina M; Moradian S; Dehghan MH; Nourinia R; Peyman GA; Yaseri M; Soheilian M
    Ophthalmol Retina; 2017; 1(2):103-110. PubMed ID: 31047266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
    Karasu B; Gunay BO
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.